# US 2023/0066014 A1 · Substituted nucleoside analogs as prmt5 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0066014 A1
- Document ID: US20230066014A1
- Status: Published application
- Kind: A1
- Application number: 17/782,214
- Filed: 2020-12-02
- Published: 2023-03-02
- Earliest claimed: 2019-12-03
- Assignees: Lupin Limited
- Applicants: Lupin Limited
- Inventors: Prathap Sreedharan NAIR; Ganesh Bhausaheb GUDADE; Shankar Bhaskar BHAGWAT; Amol Maruti YADAV; Chaitanya Prabhakar KULKARNI; Milind Dattatraya SINDKHEDKAR; Venkata P. PALLE; Rajender Kumar KAMBOJ
- Web page: https://patentgrep.com/patent/US20230066014A1

## CPC

- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- C07D 487/04: Ortho-condensed systems
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/536: ortho- or peri-condensed with carbocyclic ring systems
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to substituted nucleoside analogues of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions for treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme. The invention also relates to methods of treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme.

## Claims

### Claim 1

A compound of general formula (I), its stereoisomer, or its pharmaceutically acceptable salt,
wherein,
L1 is selected from —CRaRb—, —NRa—, S, and O;
Ra and Rb are independently selected at each occurrence from hydrogen, substituted or unsubstituted alkyl, and substituted or unsubstituted cycloalkyl;
ring A is selected from formula (i) to (viii), wherein the substituent R3 on ring A may be substituted on any of the ring C atoms,
Rc and Rd are substituted or unsubstituted alkyl or together with the carbon atoms to which Rc and Rd are attached form a C3-C6 cycloalkyl ring;
Hy is selected from formula (a-1) to (d-1),
R is selected from —NR4R5, substituted or unsubstituted alkyl and cycloalkyl;
R1 and R2 together with the carbon atoms to which they are attached form a bond in order to form a —C═C—; or R1 and R2 together with the carbon atoms to which they are attached form a cyclopropane ring;
R2′ and R2a which may be same or different and are independently selected at each occurrence from hydrogen and substituted or unsubstituted alkyl;
R3 is independently selected at each occurrence from halogen, cyano, nitro, substituted or unsubstituted alkyl, —OR6, —NR7R8, substituted or unsubstituted cycloalkyl, —C(O)OH, —C(O)O-alkyl, —C(O)R9, —C(O)NR7R8, —NR7C(O)R9, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl and haloalkyl;
R4 and R5 are independently selected from hydrogen, substituted or unsubstituted alkyl, and substituted or unsubstituted cycloalkyl;
R6 is selected from hydrogen, substituted or unsubstituted alkyl, and substituted or unsubstituted cycloalkyl;
R7 and R8 are independently selected from hydrogen, substituted or unsubstituted alkyl, and substituted or unsubstituted cycloalkyl;
R9 is selected from substituted or unsubstituted alkyl and substituted or unsubstituted cycloalkyl;
R10 is selected from hydrogen, halogen, and substituted or unsubstituted alkyl;
‘m’ is an integer ranging from 0 to 1, both inclusive;
‘n’ is an integer ranging from 0 to 4, both inclusive;
when an alkyl group is substituted, it is substituted with 1 to 4 substituents independently selected from oxo (═O), halogen, cyano, cycloalkyl, aryl, heteroaryl, heterocyclyl, —OR7a, —C(═O)OH, —C(═O)O (alkyl), —NR8aR8b, —NR8aC(═O)R9a, and —C(═O)NR8aR8b;
when the heteroaryl group is substituted, it is substituted with 1 to 4 substituents independently selected from halogen, cyano, alkyl, haloalkyl, perhaloalkyl, cycloalkyl, heterocyclyl, —OR7a, —NR8aR8b—NR7aC(═O)R9a, —C(═O)NR8aR8b;
when the aryl group is substituted, it is substituted with 1 to 4 substituents independently selected from halogen, cyano, alkyl, haloalkyl, perhaloalkyl, cycloalkyl, heterocyclyl, —OR7a, —NR8aR8b—NR7aC(═O)R9a, —C(═O)NR8aR8b;
when the cycloalkyl group is substituted, it is substituted with 1 to 4 substituents independently selected from halogen, cyano, alkyl, haloalkyl, perhaloalkyl, —OR7a, —NR8aR8b, —NR7aC(═O)R9a, —C(═O)NR8aR8b;
R7a is selected from hydrogen, alkyl, perhaloalkyl, and cycloalkyl;
R8a and R8b are each independently selected from hydrogen, alkyl, and cycloalkyl; and
R9a is selected from alkyl and cycloalkyl.

### Claim 2 (depends on 1)

The compound of claim 1 having the structure of formula (II), its stereoisomer, or its pharmaceutically acceptable salt,
wherein,
Ring A, Hy, L1, R2a, R2′, Ra, Rb, R3 and n are as defined herein above.

### Claim 3 (depends on 1)

The compound of claim 1 having the structure of formula (III), its stereoisomer, or its pharmaceutically acceptable salt,
wherein, L1 is —CRaRb— or O;
Ring A is
Hy is selected from formula (a-1), (b-1) and (d-1),
R is selected from —NR4R5, substituted or unsubstituted alkyl and cycloalkyl; R4 and R5 are independently selected from hydrogen; R2′ is hydrogen; R3 is independently selected at each occurrence from halogen, substituted or unsubstituted alkyl, —OR6 and —NR7R8; R7 and R8 are independently selected from hydrogen; R10 is hydrogen; ‘m’ is 1; ‘n’ is an integer ranging from 0 to 3, both inclusive;

### Claim 4 (depends on 1)

The compound of claim 1, wherein R is methyl.

### Claim 5 (depends on 1)

The compound of formula (I), its stereoisomer, or its pharmaceutically acceptable salt, as claimed in claim 1, wherein the compound is selected from:
(1S,2R,5R)-3-(2-(2-Amino-3-chloro-5-fluoroquinolin-7-yl)ethyl)-5-(2-amino-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopent-3-ene-1,2-diol;
(1S,2R,5R)-3-(((2-Amino-3-chloro-5-fluoroquinolin-7-yl)oxy)methyl)-5-(2-amino-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopent-3-ene-1,2-diol;
(1S,2R,5R)-5-(4-Amino-2-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3-(((2-amino-3-chloro-5-fluoroquinolin-7-yl)oxy)methyl)cyclopent-3-ene-1,2-diol;
(1S,2R,5R)-3-(2-(2-Amino-3-chloro-5-fluoroquinolin-7-yl)ethyl)-5-(6-amino-4-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)cyclopent-3-ene-1,2-diol;
(1S,2R,5R)-5-(4-Amino-2-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3-(((6-(difluoromethyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)methyl)cyclopent-3-ene-1,2-diol;
(1S,2R,5R)-5-(4-Amino-2-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3-(2-(6-(difluoromethyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)ethyl)cyclopent-3-ene-1,2-diol;
(1S,2R,5R)-5-(4-Amino-2-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3-(2-(2-amino-3-chloro-5-fluoroquinolin-7-yl)ethyl)cyclopent-3-ene-1,2-diol, and
(1S,2R,5R)-5-(2-Amino-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3-(2-(6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)ethyl)cyclopent-3-ene-1,2-diol.

### Claim 6 (depends on 1)

The pharmaceutical composition comprising at least one compound of claim 1, its stereoisomer, or its pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier.

### Claim 7 (depends on 1)

The method for treating a disease, disorder, syndrome or condition associated with PRMT5 enzyme, comprising administering to a subject in need thereof an effective amount of compound as claimed in claim 1.

### Claim 8 (depends on 7)

A method as claimed in claim 7, wherein the said disease, disorder, syndrome, or condition associated with PRMT5 enzyme is glioblastoma multiforme, prostate cancer, pancreatic cancer, mantle cell lymphoma, non-Hodgkin's lymphomas and diffuse large B-cell lymphoma, acute myeloid leukemia, acute lymphoblastic leukemia, multiple myeloma, non-small cell lung cancer, small cell lung cancer, breast cancer, triple negative breast cancer, gastric cancer, colorectal cancer, ovarian cancer, bladder cancer, hepatocellular cancer, melanoma, sarcoma, oropharyngeal squamous cell carcinoma, chronic myelogenous leukemia, epidermal squamous cell carcinoma, nasopharyngeal carcinoma, neuroblastoma, endometrial carcinoma, and cervical cancer.

### Claim 9 (depends on 7)

The method as claimed in claim 7, wherein the said disease, disorder, syndrome, or condition associated with PRMT5 enzyme is cancer.

### Claim 10 (depends on 1)

Use of a compound of claim 1, or pharmaceutically acceptable salt thereof in the preparation of medicament for treating a disease, disorder, syndrome or condition associated with PRMT5.

### Claim 11 (depends on 10)

The use as claimed in claim 10, wherein the disease, disorder, syndrome, or condition associated with PRMT5 are selected from the group consisting of glioblastoma multiforme, prostate cancer, pancreatic cancer, mantle cell lymphoma, non-Hodgkin's lymphomas and diffuse large B-cell lymphoma, acute myeloid leukemia, acute lymphoblastic leukemia, multiple myeloma, non-small cell lung cancer, small cell lung cancer, breast cancer, triple negative breast cancer, gastric cancer, colorectal cancer, ovarian cancer, bladder cancer, hepatocellular cancer, melanoma, sarcoma, oropharyngeal squamous cell carcinoma, chronic myelogenous leukemia, epidermal squamous cell carcinoma, nasopharyngeal carcinoma, neuroblastoma, endometrial carcinoma, and cervical cancer.

### Claim 12 (depends on 10)

The use as claimed in claim 10, wherein the disease, disorder, syndrome, or condition associated with PRMT5 is cancer.
